{"id":"doi:10.1111/apt.15316","kind":"article","title":"Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity","authors":["Philip Noel Newsome","Sven Francque","Stephen A. Harrison","Vlad Ratziu","Luc Van Gaal","Salvatore Calanna","Morten Hansen","Martin Linder","Arun Jayant Sanyal"],"author_count":9,"year":2019,"published":"2019-06-10","venue":"Alimentary Pharmacology & Therapeutics","cited_by":186,"doi":"10.1111/apt.15316","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1111/apt.15316","archive_url":"https://space-kitty.com/papers/doi:10.1111/apt.15316","updated":null,"pmid":"31246368","pmcid":"PMC6617813","openalex_id":"W2954905478","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/apt.15316","abstract":"BACKGROUND: Obesity and type 2 diabetes are drivers of non-alcoholic fatty liver disease (NAFLD). Glucagon-like peptide-1 analogues effectively treat obesity and type 2 diabetes and may offer potential for NAFLD treatment. AIM: To evaluate the effect of the glucagon-like peptide-1 analogue, semaglutide, on alanine aminotransferase (ALT) and high-sensitivity C-reactive protein (hsCRP) in subjects at risk of NAFLD. METHODS: Data from a 104-week cardiovascular outcomes trial in type 2 diabetes (semaglutide 0.5 or 1.0 mg/week) and a 52-week weight management trial (semaglutide 0.05-0.4 mg/day) were analysed. Treatment ratios vs placebo were estimated for ALT (both trials) and hsCRP (weight management trial only) using a mixed model for repeated measurements, with or without adjustment for change in body weight. RESULTS: Elevated baseline ALT (men >30 IU/L; women >19 IU/L) was present in 52% (499/957) of weight management trial subjects. In this group with elevated ALT, end-of-treatment ALT reductions were 6%-21% (P<0.05 for doses≥0.2 mg/day) and hsCRP reductions 25%-43% vs placebo (P < 0.05 for 0.2 and 0.4 mg/day). Normalisation of elevated baseline ALT occurred in 25%-46% of weight management trial subjects, vs 18% on placebo. Elevated baseline ALT was present in 41% (1325/3268) of cardiovascular outcomes trial subjects. In this group with elevated ALT, no significant ALT reduction was noted at end-of-treatment for 0.5 mg/week, while a 9% reduction vs placebo was seen for 1.0 mg/week (P = 0.0024). Treatment ratios for changes in ALT and hsCRP were not statistically significant after adjustment for weight change. CONCLUSIONS: Semaglutide significantly reduced ALT and hsCRP in clinical trials in subjects with obesity and/or type 2 diabetes.","abstract_license":"CC-BY (publisher license, via OpenAlex)","license":"cc-by","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Liver Disease Diagnosis and Treatment"],"details":null,"provenance":"openalex+europepmc","attribution":"Abstract of \"Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity\" by Philip Noel Newsome, Sven Francque, Stephen A. Harrison et al., https://doi.org/10.1111/apt.15316, used under its Creative Commons Attribution license (CC-BY); markup removed, otherwise unmodified.","topics":[{"slug":"glp1-metabolic","name":"GLP-1 & Incretin Therapies","domain_slug":"medicine"}],"cited_in_dossiers":[]}